Clinical Trial Search

Primary: Change From Baseline to Week 8 in the 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score — -13.2; -12.6; -14.7 units on a scale — p=0.494

Primary: Number of Participants With Adverse Events (AEs) — 43; 27; 5; 17 Participants

Primary: pQCT of Lower Leg — -2.19; 0.04; -2.09; -0.30 Z-score — p=0.0003

Primary: Absolute Change From Baseline to Week 12 in Total Lesion Counts. — -57.2; -60.8; -49.8 lesion count — p=<0.001

Primary: Cmax of Serum Testosterone — 830; 1050; 883 ng/dL

Primary: Craving as Assessed by the Brief Substance Craving Scale (BSCS) — 5.57; 6.23; 5.00; 5.08 units on a scale

Primary: Overall Response Rate Among Patients With Salvage Brentuximab Vedotin (BV) — 75.0 percentage of participants with response

Primary: Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score at Day 30 — 12.6; 14.8 units on a scale — p==0.0073

Primary: Percent Increase From Mean Baseline (07:00 to 19:00) of Cerebrospinal Fluid (CSF) Amyloid Beta During Sleep Induction and Sleep Deprivation Between 01:00 and 11:00 From…

Primary: Percent Correct Words Identified — 98.6; 97.1; 91.9; 98.8 percentage of words identified

Primary: Number of Participants Who Had Access to, and Received the Intervention — 50 Participants

Primary: Modified Rankin Scale — 3.5; 3.7 units on a scale

Primary: Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score at Day 30 — 13.4; 15.8 units on a scale — p==0.0030

Primary: Percentage of Participants With American College of Rheumatology 20% (ACR20) Response — 34.4; 33.5; 31.5 percentage of participants

Primary: Change From Baseline to 24 Week Endpoint in Appendicular Lean Body Mass (aLBM) — 0.303; -0.123 kilograms (kg) — p=<0.001